CoChat
Sign Up
Cited by 525Radiopharmaceutical Chemistry and ApplicationsLymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

The DOI matches its Crossref record; 51 of the 56 references it cites were found in a registry or an index.

Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience

Kaminski, Mark S., Estes, Judith, Zasadny, Kenneth R., Francis, Isaac R., Ross, Charles W., Tuck, Melissa, Regan, Denise, Fisher, Susan, Gutierrez, Jeanne, Kroll, Stewart, Stagg, Robert, Tidmarsh, George, Wahl, Richard L.·2000·Blood
DOI 10.1182/blood.v96.4.1259
Open this paper in CoChat — free account

Abstract

CD20-targeted radioimmunotherapy is a promising new treatment for B-cell non-Hodgkin lymphoma (NHL). We now provide updated and long-term data on 59 chemotherapy-relapsed/refractory patients treated with iodine (131)I tositumomab in a phase I/II single-center study. Fifty-three patients received individualized therapeutic doses, delivering a specified total-body radiation dose (TBD) based on the clearance rate of a preceding dosimetric dose. Six patients received dosimetric doses only. Dose-escalations of TBD were conducted separately in patients who had or had not undergone a prior autologous stem cell transplant (ASCT) until a nonmyeloablative maximally tolerated TBD was established (non-ASCT = 75 cGy, post-ASCT = 45 cGy). Fourteen additional non-ASCT patients were treated with 75 cGy. Unlabeled antibody was given prior to labeled dosimetric and therapeutic doses to improve biodistribution. Forty-two (71%) of 59 patients responded; 20 (34%) had complete responses (CR). Thirty-five (83%) of 42 with low-grade or transformed NHL responded versus 7 (41%) of 17 with de novo intermediate-grade NHL (P =.005). For all 42 responders, the median progression-free survival was 12 months, 20.3 for those with CR. Seven patients remain in CR 3 to 5.7 years. Sixteen patients were re-treated after progression; 9 responded and 5 had a CR. Reversible hematologic toxicity was dose limiting. Only 10 patients (17%) had human anti-mouse antibodies detected. Long-term, 5 patients developed elevated thyroid-stimulating hormone levels, 5 were diagnosed with myelodysplasia and 3 with solid tumors. A single, well-tolerated treatment with iodine (131)I tositumomab can, therefore, produce frequent and durable responses in NHL, especially low-grade or transformed NHL. (Blood. 2000;96:1259-1266)

Overview

Integrity signals

Registry

Crossref · 10.1182/blood.v96.4.1259

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 56 references

Research works printed but not linked: 7

  1. Maloney, 1996, The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines [abstract]., Blood., 88, 637a
  2. Kolstad, 1999, Characterization of the apoptotic process initiated by ligation of CD20 by the mouse monoclonal antibody Anti-B1 in the Burkitt's lymphoma cell line Ramos [abstract]., Blood., 94, 87a
  3. Wiseman, 1999, Therapeutic index of IDEC-Y2B8 radioimmunotherapy: up to 850 fold greater radiation dose to tumor than to normal organs [abstract]., Proc Am Soc Clin Oncol., 18, 4a
  4. Gates, 1998, Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy., J Nucl Med., 39, 1230
  5. Kaminski, 1997, A multicenter phase II study of Iodine-131 anti-B1 antibody (Bexxar) in patients with chemotherapy-relapsed/refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphoma [abstract]., Blood., 90, 509a
  6. Kaminski, 1998, Multicenter, phase III study of iodine-131 tositumomab (Anti-B1 Antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma [abstract]., Blood., 92, 316a
  7. Kaminski, 1997, Front-line treatment of advanced B-cell low-grade lymphoma with radiolabeled anti-B1 antibody: initial experience [abstract]., Am Soc Clin Oncol., 16, 51a

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Kaminski, M. S., Estes, J., Zasadny, K. R., Francis, I. R., Ross, C. W., Tuck, M., Regan, D., Fisher, S., Gutierrez, J., Kroll, S., Stagg, R., Tidmarsh, G., & Wahl, R. L.
Affiliations
University of Michigan (US)
ORCID
Venue
Blood
Publisher
American Society of Hematology
Published
2000-08-15
Volume
96
Issue
4
Pages
1259-1266
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood.v96.4.1259
OpenAlex
W1573890015
Cited by
525
References
56
Citations by year
2025: 1 · 2024: 9 · 2023: 7 · 2022: 7 · 2021: 4 · 2020: 13 · 2019: 7 · 2018: 7 · 2017: 11 · 2016: 15 · 2015: 14 · 2014: 17 · 2013: 14 · 2012: 21
FWCI
41.15
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01ca056794-08)
  • National Cancer Institute (R01-CA-56794, P01-CA-42678)
  • National Center for Research Resources (M-01RR00042, M01RR000042)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
radioimmunotherapy, iodine-131 tositumomab, B-cell non-Hodgkin lymphoma, relapsed/refractory lymphoma, autologous stem cell transplantation, progression-free survival, complete response, long-term follow-up, hematologic toxicity, human anti-mouse antibodies, thyroid-stimulating hormone, myelodysplastic syndrome
MeSH terms
Adult, Aged, Antibodies, Monoclonal, Female, Follow-Up Studies, Humans, Iodine Radioisotopes, Male, Middle Aged, Recurrence, Lymphoma, B-Cell, Radioimmunotherapy, Treatment Outcome, Antigens, CD20

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review